Company logo

KURA - Kura Oncology, Inc.

NASDAQ -> Healthcare -> Biotechnology
San Diego, United States
Type: Equity

KURA price evolution
KURA
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Current assets
Cash $45.18 $41.51 $37.32
Short term investments $446.34 $485.62 $386.64
Net receivables
Inventory
Total current assets $463.19 $499.77 $537.84 $432.48
Long term investments
Property, plant & equipment $7.42 $7.92 $8.41 $8.85
Goodwill & intangible assets
Total noncurrent assets $15.35 $16.07 $16.45
Total investments $446.34 $485.62 $386.64
Total assets $478.84 $515.12 $553.91 $448.94
Current liabilities
Accounts payable $3.01 $31.14 $30.9 $33.76
Deferred revenue
Short long term debt $2.31 $1.36 $1.51
Total current liabilities $40.37 $33.45 $32.27 $35.26
Long term debt $7.76 $14.42 $15.61 $15.69
Total noncurrent liabilities $15.6 $16.56 $16.4
Total debt $16.73 $16.97 $17.2
Total liabilities $55.07 $49.05 $48.82 $51.66
Shareholders' equity
Retained earnings -$876.21 -$821.8 -$770.96 -$721.44
Other shareholder equity $1.12 -$0.46 -$0.82 -$1.27
Total shareholder equity $466.07 $505.08 $397.27
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $37.32 $52.01 $90.88 $325.7
Short term investments $386.64 $386.18 $427.29 $307.83
Net receivables
Inventory
Total current assets $432.48 $446.43 $522.29 $637.29
Long term investments
Property, plant & equipment $8.85 $6.38 $8.25 $8.36
Goodwill & intangible assets
Total noncurrent assets $16.45 $9.88 $11.76 $9.92
Total investments $386.64 $386.18 $427.29 $307.83
Total assets $448.94 $456.31 $534.05 $647.21
Current liabilities
Accounts payable $33.76 $1.53 $22.45 $23.02
Deferred revenue
Short long term debt $1.51 $2.32 $3
Total current liabilities $35.26 $24.06 $22.45 $26.02
Long term debt $15.69 $9.16 $4.61 $9.89
Total noncurrent liabilities $16.4 $11.97 $4.99 $10.28
Total debt $17.2 $14.02 $4.61 $12.89
Total liabilities $51.66 $36.03 $27.44 $36.31
Shareholders' equity
Retained earnings -$721.44 -$568.81 -$432.97 -$302.5
Other shareholder equity -$1.27 -$8.03 -$1.79 $0.05
Total shareholder equity $397.27 $420.28 $506.61 $610.9
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $39.73 $36.27 $32.53
Selling, general & administrative $16.68 $18.18 $14.23
Total operating expenses $59.88 $56.4 $54.45 $46.76
Operating income -$56.4 -$54.45 -$46.76
Income from continuing operations
EBIT -$50.43 -$49.13 -$42.39
Income tax expense
Interest expense $5.48 $0.41 $0.4 $0.39
Net income
Net income -$54.4 -$50.84 -$49.52 -$42.79
Income (for common shares) -$50.84 -$49.52 -$42.79
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $115.23 $92.81 $84.72 $60.4
Selling, general & administrative $50.57 $47.05 $46.54 $31.5
Total operating expenses $165.8 $139.87 $131.26 $91.9
Operating income -$165.8 -$139.87 -$131.26 -$91.9
Income from continuing operations
EBIT -$151.08 -$135.61 -$130.05 -$89.05
Income tax expense
Interest expense $1.55 $0.23 $0.41 $0.58
Net income
Net income -$152.63 -$135.84 -$130.47 -$89.63
Income (for common shares) -$152.63 -$135.84 -$130.47 -$89.63
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Net income -$50.84 -$49.52 -$42.79
Operating activities
Depreciation $0.2 $0.23 $0.21
Business acquisitions & disposals
Stock-based compensation $8.43 $8.51 $7.17
Total cash flows from operations -$42.53 -$48.84 -$34.31
Investing activities
Capital expenditures -$0.02 -$0.08 -$0.02
Investments $43.18 -$95.25 $42.21
Total cash flows from investing -$6.63 $43.17 -$95.34 $42.2
Financing activities
Dividends paid
Sale and purchase of stock $3.04 $148.37 $0.69
Net borrowings
Total cash flows from financing $153.61 $3.04 $148.37 $0.69
Effect of exchange rate
Change in cash and equivalents $12.16 $3.68 $4.19 $8.58
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$152.63 -$135.84 -$130.47 -$89.63
Operating activities
Depreciation $0.85 $0.76 $0.56 $0.19
Business acquisitions & disposals
Stock-based compensation $28.08 $26.32 $23.58 $12.81
Total cash flows from operations -$124.82 -$110.06 -$104.55 -$69.83
Investing activities
Capital expenditures -$0.17 -$0.63 -$1.15 -$2.17
Investments $15.72 $33.25 -$125.69 -$97.77
Total cash flows from investing $15.56 $32.63 -$126.83 -$99.94
Financing activities
Dividends paid
Sale and purchase of stock $94.78 $29.14 $4.43 $469.58
Net borrowings $9.43 -$7.86 -$0.25
Total cash flows from financing $94.78 $38.56 -$3.44 $469.33
Effect of exchange rate
Change in cash and equivalents -$14.48 -$38.87 -$234.82 $299.57
News
Kura Oncology, Inc. (KURA): This Small-Cap Healthcare Stock Is A Good Buy Right...
Insider Monkey · via Yahoo Finance 21 Aug 2024
Estimating The Intrinsic Value Of Kura Oncology, Inc. (NASDAQ:KURA)
Simply Wall St. · via Yahoo Finance 20 Jun 2024
2 Incredible Growth Stocks to Buy Hand Over Fist
Motley Fool via Yahoo Finance 8 May 2024
Kura Oncology, Inc. (NASDAQ:KURA) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance 6 May 2024
Kura Oncology, Inc. (NASDAQ:KURA) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance 28 Feb 2024
Chief Medical Officer Stephen Dale Sells Shares of Kura Oncology Inc
GuruFocus.com via Yahoo Finance 4 Feb 2024
Is There An Opportunity With Kura Oncology, Inc.'s (NASDAQ:KURA) 42% Undervaluation?
Simply Wall St. via Yahoo Finance 28 Jan 2024
Why Is Cancer Focused Kura Oncology Stock Is Trading Higher Today?
Benzinga via Yahoo Finance 21 Jan 2024
14 Best Cancer Stocks To Buy Now
Insider Monkey via Yahoo Finance 9 Oct 2023
An Intrinsic Calculation For Kura Oncology, Inc. (NASDAQ:KURA) Suggests It's 48% Undervalued
Simply Wall St. via Yahoo Finance 6 Jan 2023
Fundamentals
Market cap $782.15M
Enterprise value N/A
Shares outstanding 77.75M
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income -$197.55M
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio -3.96
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS -$2.54
ROA -39.57%
ROE N/A
Debt/Equity 0.13
Net debt/EBITDA N/A
Current ratio 11.47
Quick ratio N/A